Top

Published in:

01-07-2009 | Letter to the Editor

No association of miscarriage and BRCA carrier status in Pakistani breast/ovarian cancer patients with a history of parental consanguinity

Authors: Muhammad U. Rashid, Diana Torres, Farah Rasheed, Faisal Sultan, Abdul R. Shakoori, Asim Amin, Klaus Schlaefer, Ute Hamann

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Excerpt

To the editor …

Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, the Breast Cancer Linkage Consortium (1995) An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 56:254–264PubMed

Narod S, Ford D, Devilee P, Barkardottir RB, Eyfjord J, Lenoir G et al (1995) Genetic heterogeneity of breast-ovarian cancer revisited. Am J Hum Genet 57:957–958PubMed

Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, the Breast Cancer Linkage Consortium (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689. doi:10.1086/301749 PubMedCrossRef

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130. doi:10.1086/375033 PubMedCrossRef

Friedman E, Bar-Sade Bruchim R, Kruglikova A, Risel S, Levy-Lahad E, Halle D et al (1998) Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet 63:1224–1227. doi:10.1086/302040 PubMedCrossRef

Kuschel B, Gayther SA, Easton DF, Ponder BA, Pharoah PD (2001) Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing. Genes Chromosomes Cancer 31:96–98. doi:10.1002/gcc.1122 PubMedCrossRef

Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH (1996) Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 12:191–194. doi:10.1038/ng0296-191 PubMedCrossRef

Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R et al (1997) Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 11:1242–1252. doi:10.1101/gad.11.10.1242 PubMedCrossRef

Gal I, Sadetzki S, Gershoni-Baruch R, Oberman B, Carp H, Papa MZ et al (2004) Offspring gender ratio and the rate of recurrent spontaneous miscarriages in Jewish women at high risk for breast/ovarian cancer. Am J Hum Genet 74:1270–1275. doi:10.1086/421442 PubMedCrossRef

10.

Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Hereditary Breast Cancer Clinical Study Group et al (2006) Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res 8:R15. doi:10.1186/bcr1387 PubMedCrossRef

11.

Hashmi MA (1997) Frequency of consanguinity and its effect on congenital malformation—a hospital based study. J Pak Med Assoc 47:75–78PubMed

12.

Hussain R, Bittles AH (1998) The prevalence and demographic characteristics of consanguineous marriages in Pakistan. J Biosoc Sci 30:261–275. doi:10.1017/S0021932098002612 PubMedCrossRef

13.

Rashid MU, Zaidi A, Torres D, Sultan F, Benner A, Naqvi B et al (2006) Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int J Cancer 119:2832–2839. doi:10.1002/ijc.22269 PubMedCrossRef

14.

World Health Organization. WHO: recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths (1977) Modifications recommended by FIGO as amended October 14, 1976. Acta Obstet Gynecol Scand 56:247–253

15.

Abdulrazzaq YM, Bener A, al-Gazali LI, al-Khayat AI, Micallef R, Gaber T (1997) A study of possible deleterious effects of consanguinity. Clin Genet 51:167–173PubMedCrossRef

16.

Al Husain M, al Bunyan M (1997) Consanguineous marriages in a Saudi population and the effect of inbreeding on prenatal and postnatal mortality. Ann Trop Paediatr 17:155–160PubMed

17.

Demirel S, Kaplanoğlu N, Acar A, Bodur S, Paydak F (1997) The frequency of consanguinity in Konya, Turkey, and its medical effects. Genet Couns 8:295–301PubMed

18.

Bittles AH, Grant JC, Shami SA (1993) Consanguinity as a determinant of reproductive behaviour and mortality in Pakistan. Int J Epidemiol 22:463–467. doi:10.1093/ije/22.3.463 PubMedCrossRef

Title: No association of miscarriage and BRCA carrier status in Pakistani breast/ovarian cancer patients with a history of parental consanguinity
Authors: Muhammad U. Rashid
Diana Torres
Farah Rasheed
Faisal Sultan
Abdul R. Shakoori
Asim Amin
Klaus Schlaefer
Ute Hamann
Publication date: 01-07-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0095-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2009

Pharmaceuticals that cause mammary gland tumors in animals: findings in women

Expression of TNF-α leader sequence renders MCF-7 tumor cells resistant to the cytotoxicity of soluble TNF-α

Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways

Comments on: Yin W, Di G, Zhou L, Lu J, Liu G, Wu J, Shen K, Han Q, Shen Z, Shao Z. Time-varying pattern of recurrence risk for Chinese breast cancer patients

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial

Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer